Summary: Elevated cholesterol is one of the main modifiable factors in the development of cardiovascular diseases. However, its increased risk leads to cardiovascular incidents caused by atherosclerosis, most often heart attacks and strokes. The most important goal of cholesterol lowering therapy is to achieve the target LDL cholesterol levels. The currently available PCSK9 inhibitors in combination with statins and ezetimibe are an excellent means of achieving the recommended LDL cholesterol level. The article below presents answers to the most frequently asked questions about the drug program – "Treatment of patients with lipid disorders with PCSK9 inhibitors".